BioNTech share after the EU breakthrough: what’s next?

Yesterday it seemed as if the EU Commission had only been waiting for the recommendation of the European Medicines Agency on BioNTech’s COVID-19 vaccine BNT162. No sooner had she recommended that the vaccine be approved than the emergency approval came from the commission. For normal working speeds in Brussels, that was the speed of light and that also shows the drama of the situation: BioNTech’s vaccine is needed and better yesterday than today. The vaccinations should now be started as soon as possible. This morning BioNTechs will also comment on the developments in a press conference.

For the Mainz-based biotech company and its partner Pfizer, this was the last major market in which BNT162 was not yet approved. China is being plowed by BioNTech together with Fosun Pharma. And with the share price of Rheinhessen, what we have been warning about for some time happened: Not much. On the NASDAQ, the share price fluctuated between $ 104.57 and $ 107.97 yesterday. At the current valuation level, investors on the stock market seem to see a lot of the latest good news priced in. That the surprise effect of the last decisions was missing – hardly anyone right, for example, that the Emergency approval in Europe is refused – is added.


Related Articles

Back to top button